A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease

Autor: Lucia Pacifico, Paolo Versacci, M. Di Martino, Gianmarco Andreoli, Enea Bonci, Claudio Chiesa, Lucia Martina Silvestri
Rok vydání: 2015
Předmět:
Male
Biopsy
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Medicine (miscellaneous)
Adipose tissue
Overweight
Ventricular Function
Left
Body Mass Index
Non-alcoholic Fatty Liver Disease
Risk Factors
Nonalcoholic fatty liver disease
Insulin
visceral adipose tissue
Child
diabetes and metabolism
Nutrition and Dietetics
Fatty liver
Alanine Transaminase
Fasting
docosahexaenoic acid
epicardial adipose tissue
Magnetic Resonance Imaging
Treatment Outcome
Adipose Tissue
Liver
Docosahexaenoic acid
Fatty Acids
Unsaturated
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
Pericardium
medicine.medical_specialty
Adolescent
Docosahexaenoic Acids
Intra-Abdominal Fat
Placebo
endocrinology
Double-Blind Method
children
NAFLD
Internal medicine
medicine
Humans
Triglycerides
business.industry
liver fat
medicine.disease
Obesity
cardiac function
medicine (miscellaneous)
nutrition and dietetics
endocrinology
diabetes and metabolism
cardiology and cardiovascular medicine
Endocrinology
business
Zdroj: NMCD. Nutrition Metabolism and Cardiovascular Diseases (Testo stamp.) 25 (2015): 734–741. doi:10.1016/j.numecd.2015.04.003
info:cnr-pdr/source/autori:Pacifico, L.; Bonci, E.; Di Martino, M.; Versacci, P.; Andreoli, G.; Silvestri, L. M.; Chiesa, C./titolo:A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease/doi:10.1016%2Fj.numecd.2015.04.003/rivista:NMCD. Nutrition Metabolism and Cardiovascular Diseases (Testo stamp.)/anno:2015/pagina_da:734/pagina_a:741/intervallo_pagine:734–741/volume:25
ISSN: 0939-4753
DOI: 10.1016/j.numecd.2015.04.003
Popis: Background and Aims Very little information is available on whether docosahexaenoic acid (DHA) supplementation has a beneficial effect on liver fat and cardiovascular disease (CVD) risk factors in children with nonalcoholic fatty liver disease (NAFLD). In a double-blind, placebo-controlled randomized trial we investigated whether 6-month treatment with DHA improves hepatic fat and other fat depots, and their associated CVD risk factors in children with biopsy-proven NAFLD. Methods and Results Of 58 randomized children, 51 (25 DHA, 26 placebo) completed the study. The main outcome was the change in hepatic fat fraction as estimated by magnetic resonance imaging. Secondary outcomes were changes in visceral adipose tissue (VAT), epicardial adipose tissue (EAT), and left ventricular (LV) function, as well as alanine aminotransferase (ALT), triglycerides, body mass index-standard deviation score (BMI-SDS), and insulin sensitivity. At 6 months, the liver fat was reduced by 53.4% (95% CI, 33.4–73.4) in the DHA group, as compared with 22.6% (6.2–39.0) in the placebo group ( P = 0.040 for the comparison between the two groups). Likewise, in the DHA group VAT and EAT were reduced by 7.8% (0–18.3) and 14.2% (0–28.2%), as compared with 2.2% (0–8.1) and 1.7% (0–6.8%) in the placebo group, respectively ( P = 0.01 for both comparisons). There were no significant between-group changes for LV function as well as BMI-SDS and ALT, while fasting insulin and triglycerides significantly decreased in the DHA-treated children ( P = 0.028 and P = 0.041, respectively). Conclusions DHA supplementation decreases liver and visceral fat, and ameliorates metabolic abnormalities in children with NAFLD.
Databáze: OpenAIRE
Externí odkaz: